About Me

I am a geneticist with expertise in clinical molecular genetics and clinical cytogenetics. My primary specialty is the use of molecular cytogenetics and molecular pathology to diagnose cancer.

Read more

Molecular cytogenetics is a continually expanding field due to the rapid progress in cancer genetics research. I closely monitor the new diagnostic and prognostic markers emerging from translational research in order to promptly develop the needed assays for clinical testing of patients.

My investigative research in cancer genetics involves the detection and cloning of new recurrent genomic rearrangements in human cancers. The goal of my work is to identify novel pathogenic molecules that can be used for genetic diagnosis of cancer and lead to improvement in the care of cancer patients.

  • Clinical Expertise: Clinical Molecular Genetics and Cancer Cytogenetics
  • Languages Spoken: English
  • Education: MD, Shandong University School of Medicine (China); PhD, Shanghai Institute of Hematology, Shanghai Second Medical University (China)
  • Fellowships: Weill Cornell Medical College; Memorial Sloan Kettering Cancer Center
  • Board Certifications: Clinical Molecular Genetics

New Patient Appointments

Making an appointment

Call 800-525-2225


Wang L, Su XY, Cao Q, Chen SJ, Zhang LJ, Wang G, Zhao XT, Wan DF, Gu JR. Application of Comparative Genomic Hybridization for detection of genomic imbalance in tumors. Acta University of Yunnan. 1999, 21: 345-346 [in Chinese]

Wang G, Zhao Y, Liu X, Wang L, Wu C, Zhang W, Liu W, Zhang P, Cong W, Zhu Y, Zhang L, Chen S, Wan D, Zhao X, Huang W, Gu JR. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes & Cancer. 2001; 31: 221-7  (Wang G, Zhao Y, Liu X and Wang L contributed equally to this work)    
Hou SL, Wang L. Chen SJ, Wang YL. Advanced research in clinical related genes in Non-Hodgkin Lymphoma. [Chinese] Foreign Medical Sciences —- Genetics. 2003, 26(2):72-76
Read more
Zhu YS, Cai LQ, Huang Y, Fish J, Wang L, Zhang ZK, Imperato-McGinley JL . Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens. Journal of Andrology. 2005; 26: 500-8.
Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan EV,  Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009; 28: 2773-83.
Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jun 5;43(7):668-72
Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J,  Dal Cin P, Antonescu C, Singer S, Hameed M, Bovee J, Hogendoorn P.C.W., Socci N, Ladanyi M. Identification of a Novel, Recurrent HEY1-NCOA2 Fusion in Mesenchymal Chondrosarcoma based on a Genome-wide Screen of Exon-level Expression Data. Genes Chromosomes & Cancer. 2012 Feb;51(2):127-39
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33
Bohn OL, Whitten J, Spitzer B, Kobos R, Prockop S, Boulad F, Arcila M, Wang L, Teruya-Feldstein J. Posttransplant Lymphoproliferative Disorder Complicating Hematopoietic Stem Cell Transplantation in a Patient With Dyskeratosis Congenita. Int J Surg Pathol. 2013 Oct;21(5):520-5
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CKY, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin L-X, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FJ, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K/AKT pathway mutations. Nat Genet. 2014 Jun;46(6):595-600
Schoolmeester JK, Dao LN, Sukov WR, Wang L, Park KJ, Murali R, Hameed MR, Soslow RA. TFE3 Translocation-associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract: Morphology, Immunophenotype, Differential Diagnosis. Am J Surg Pathol. 2015 Mar;39(3):394-404

Visit PubMed for a full listing of Lu Wang’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more